Pope Leo XIV's writings verified by Proudly Human
MELBOURNE, Australia and ROME , July 21, 2026 /PRNewswire/ -- Proudly Human has today announced that Maps of Hope, a collection of speeches and writings by Pope Leo XIV on education and artificial intelligence, has been verified as human-authored,...
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 9, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was...
Allianz Global Insurance Report 2026: The Future of Insurance in a Fragmenting World
World: Global premium pool expanded by +7.1% in 2025 – an increase of EUR456bn Singapore: Strong growth of +10.7% – due to double-digit growth in life and health insurance Outlook: Private protection remains a structurally growing need ensuring...
Roubini, Longtime Crypto Skeptic, Co-Authors Whitepaper and Backs Atlas's New Digital Reserve Asset
Atlas to launch USAFi, the first regulated permissionless security, under VARA's framework in Dubai Dr. Nouriel Roubini, long one of the most prominent critics of cryptocurrencies, makes his first move into digital assets, co-authoring the...
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line...
810 million women still not using mobile internet in low- and middle-income countries, compared to 595 million men
Persistent barriers related to affordability, skills and safety concerns continue to limit women's digital inclusion in low- and middle-income countries LONDON, June 10, 2026 /PRNewswire/ -- The gender gap in mobile internet adoption narrowed...
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast...
SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies
SHANGHAI, May 27, 2026 /PRNewswire/ -- SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in Cell with...
Climate action key to affordable housing, but buildings decarbonisation stalls
NAIROBI, Kenya, May 19, 2026 /PRNewswire/ -- Decarbonisation of the buildings and construction sector has slowed, leaving it both a major emissions source and increasingly vulnerable to climate impacts and energy price shocks, according to a new...
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be...